Summary by Futu AI
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 06/06/2024, with an aggregate market value of $450,000. The shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 406,319 shares were sold for gross proceeds of approximately $3.77 million.